Figure 3. The GR90291 blood concentration versus time data for the subjects with liver disease (A) and the control subjects (B). Each dashed line represents the data from one subject, and the heavy lines are the mean values. In all groups, the concentrations of GR90291 continued to increase during the 4-h infusion of remifentanil. After termination of the remifentanil infusion, the concentrations of GR90291 gradually declined. The apparently higher concentrations of GR90291 in the subjects with liver disease compared with the control subjects in the high-dose group were not statistically different.